Ever swelling during the assessment period was a predictor of JSN recent onset in individual joints of patients treated with MTX (2.31 (1.55, 3.44)) and ADA (2.25 (1.55, 3.26)) monotherapy, but to a lesser, though not significant, extent of patients treated with the combination (1.31 (0.86, 1.99)) (Figure 1C), similar to the observed association between existing JSN and recent JE onset. This evidence concerns the gene ADA and Japanese encephalitis.